Free Webex Call
The Neuralgia Treatment Market was valued at USD 1.21 Billion in 2024, and is expected to reach USD 2.00 Billion by 2030, rising at a CAGR of 8.84%. The Global Neuralgia Treatment Market in 2023 is characterized by significant growth and advancements in the diagnosis and management of neuralgia-related conditions.The global neuralgia treatment market is driven by factors such as the rising prevalence of neurological disorders, increasing geriatric population, advancements in drug development, growing awareness about pain management, enhanced healthcare access, and the rising demand for effective treatments for chronic pain conditions like trigeminal neuralgia and postherpetic neuralgia. For instance, in June 2024, the Australian Government committed USD 19.6 million from the Medical Research Future Fund to improve primary healthcare, emphasizing chronic pain and multidisciplinary care. USD 8.8 million will support chronic pain initiatives, focusing on rural communities and adapting programs to reduce disability, enhancing healthcare access and outcomes. Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Key Market Drivers
Rising Prevalence of Neuralgia-Related Conditions
Neuralgia, a condition characterized by excruciating pain along nerve pathways, affects millions of individuals worldwide, significantly impacting their quality of life. While neuralgia encompasses various forms, including trigeminal neuralgia, postherpetic neuralgia, and diabetic neuropathy, one common trend is the rising prevalence of neuralgia-related conditions. This growing prevalence represents both a significant challenge and an opportunity for the healthcare industry.According to a 2024 Multiple Sclerosis (MS) Society study, over 150,000 people in the UK are living with multiple sclerosis (MS), with the increase attributed to improved diagnoses and longer life expectancies rather than a higher risk. The regional prevalence is: around 123,000 in England (1 in 450), 6,100 in Wales (1 in 500), 5,300 in Northern Ireland (1 in 350), and 17,400 in Scotland (1 in 300). Annually, more than 7,100 new cases are diagnosed, which averages to about 135 weekly.
Key Market Challenges
Underdiagnosis and Misdiagnosis
A major challenge is the underdiagnosis and misdiagnosis of neuralgia-related conditions. Many individuals endure their symptoms without seeking medical attention, often because they are unaware of their condition or its severity. Misdiagnosis can lead to inappropriate treatments and delays in receiving proper care.Key Market Trends
Advanced Diagnostic Tools
Early and accurate diagnosis is crucial for effective neuralgia treatment. The development of more sophisticated diagnostic tools, such as high-resolution imaging, nerve conduction studies, and genetic testing, will enable healthcare professionals to identify neuralgia-related conditions with greater precision. Timely diagnosis will lead to more targeted treatments.Key Market Players
- GSK PLC
- Pfizer Inc
- Novartis AG
- Biogen Inc
- Cadila Pharmaceuticals Ltd
- Lundbeck Pharmaceuticals Ltd
- Zydus Group (Cadila Healthcare Limited)
- Eli Lily and Company
- Allergan Inc.
- Baxter International Inc.
Report Scope:
In this report, the Global Neuralgia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:Neuralgia Treatment Market, By Treatment:
- Drug-Based
- Surgery
Neuralgia Treatment Market, By Indication:
- Diabetic Neuropathy
- Intercostal Neuralgia
- Occipital Neuralgia
- Peripheral Neuralgia
- Postherpetic Neuralgia
- Trigeminal Neuralgia
Neuralgia Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Neuralgia Treatment Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Neuralgia Treatment Market.Available Customizations:
With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.Company Information
- Detailed analysis and profiling of additional market players (up to five).
This product will be delivered within 1-3 business days.
Table of Contents
1. Product Overview
2. Research Methodology
3. Executive Summary
5. Global Neuralgia Treatment Market Outlook
6. North America Neuralgia Treatment Market Outlook
7. Europe Neuralgia Treatment Market Outlook
8. Asia-Pacific Neuralgia Treatment Market Outlook
9. South America Neuralgia Treatment Market Outlook
10. Middle East and Africa Neuralgia Treatment Market Outlook
11. Market Dynamics
12. Market Trends & Developments
13. Porter’s Five Forces Analysis
14. Competitive Landscape
Companies Mentioned
- GSK PLC
- Pfizer Inc
- Novartis AG
- Biogen Inc
- Cadila Pharmaceuticals Ltd
- Lundbeck Pharmaceuticals Ltd
- Zydus Group (Cadila Healthcare Limited)
- Eli Lily and Company
- Allergan Inc.
- Baxter International Inc
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 180 |
Published | March 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 1.21 Billion |
Forecasted Market Value ( USD | $ 2 Billion |
Compound Annual Growth Rate | 8.8% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |